Context Therapeutics Inc.
CNTXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How CNTX's past catalysts played out
Extended-release Onapristone
Refractory Endometrial Adenocarcinoma
Onapristone ER
Granulosa Cell Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Extended-release Onapristone | Phase 2 | Refractory Endometrial Adenocarcinoma | - | - |
Onapristone ER | Phase 2 | Granulosa Cell Ovarian Cancer | - | - |
Frequently asked questions
What is in Context Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Context Therapeutics Inc.'s (CNTX) pipeline across Phase 2. Its lead program is Extended-release Onapristone (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Context Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Context Therapeutics Inc. (CNTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CNTX biotech catalysts?→
Add CNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Context Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.